- United States
- /
- Medical Equipment
- /
- NasdaqGM:NPCE
NeuroPace Second Quarter 2024 Earnings: Beats Expectations
NeuroPace (NASDAQ:NPCE) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$19.3m (up 17% from 2Q 2023).
- Net loss: US$7.51m (loss narrowed by 18% from 2Q 2023).
- US$0.26 loss per share (improved from US$0.36 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NeuroPace Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) also surpassed analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 2.9% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 2 warning signs for NeuroPace that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if NeuroPace might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:NPCE
Excellent balance sheet and fair value.